Metacare Co (XKRX:118000) Piotroski F-Score: 4 (As of Sep. 13, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:118000 Metacare Co Ltd XKRX:118000
42 GF Score
Price ₩1,328.00
GF Value ₩5,177.27
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Metacare Co Piotroski F-Score?

Metacare Co XKRX:118000 -2.99% 42 Piotroski F-Score is 4 as of Sep. 13, 2026, which is at its 10-year median of 4.00. GuruFocus rates XKRX:118000 with a GF Score™ of 42/100 and a GF Value™ of ₩5,177.27 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 985 Drug Manufacturers companies, Metacare Co ranks worse than 60.81% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Metacare Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Metacare Co's Piotroski F-Score or its related term are showing as below:

XKRX:118000' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Metacare Co was 7. The lowest was 2. And the median was 4.

Metacare Co  (XKRX:118000) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Metacare Co Piotroski F-Score Related Terms


Metacare Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Metacare Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metacare Co Piotroski F-Score Chart

Metacare Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 5.00 6.00 5.00

Metacare Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 4.00 5.00 6.00 4.00

XKRX:118000 vs LLY, JNJ, ABBV: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Metacare Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metacare Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Metacare Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Metacare Co's Piotroski F-Score falls into.


XKRX:118000
42GF Score
Metacare Co Ltd XKRX:118000
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 1295.108 + -3719.201 + 417.255 + 412.462 = ₩-1,594 Mil.
Cash Flow from Operations was -117.566 + 20.232 + 2854.135 + 980.295 = ₩3,737 Mil.
Revenue was 10751.525 + 10314.871 + 10119.65 + 8761.49 = ₩39,948 Mil.
Gross Profit was 2520.851 + 2425.837 + 3299.483 + 2521.8 = ₩10,768 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(183984.992 + 199787.923 + 197964.575 + 188612.553 + 243950.405) / 5 = ₩202860.0896 Mil.
Total Assets at the begining of this year (Jun25) was ₩183,985 Mil.
Long-Term Debt & Capital Lease Obligation was ₩1,925 Mil.
Total Current Assets was ₩49,248 Mil.
Total Current Liabilities was ₩102,128 Mil.
Net Income was 479.191 + -3869.458 + -8.121 + 2930.457 = ₩-468 Mil.

Revenue was 4858.356 + 5595.963 + 5994.002 + 5761.673 = ₩22,210 Mil.
Gross Profit was 1820.185 + 2204.462 + 2564.138 + 2492.02 = ₩9,081 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(121651.386 + 130580.703 + 157820.077 + 173953.33 + 183984.992) / 5 = ₩153598.0976 Mil.
Total Assets at the begining of last year (Jun24) was ₩121,651 Mil.
Long-Term Debt & Capital Lease Obligation was ₩51,104 Mil.
Total Current Assets was ₩24,341 Mil.
Total Current Liabilities was ₩9,106 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Metacare Co's current Net Income (TTM) was -1,594. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Metacare Co's current Cash Flow from Operations (TTM) was 3,737. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=-1594.376/183984.992
=-0.00866579

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-467.931/121651.386
=-0.00384649

Metacare Co's return on assets of this year was -0.00866579. Metacare Co's return on assets of last year was -0.00384649. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Metacare Co's current Net Income (TTM) was -1,594. Metacare Co's current Cash Flow from Operations (TTM) was 3,737. ==> 3,737 > -1,594 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=1924.82/202860.0896
=0.00948841

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=51103.738/153598.0976
=0.33271075

Metacare Co's gearing of this year was 0.00948841. Metacare Co's gearing of last year was 0.33271075. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=49248.286/102128.411
=0.48221925

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=24340.755/9105.543
=2.67317995

Metacare Co's current ratio of this year was 0.48221925. Metacare Co's current ratio of last year was 2.67317995. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Metacare Co's number of shares in issue this year was 17.933. Metacare Co's number of shares in issue last year was 1.724. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=10767.971/39947.536
=0.26955282

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9080.805/22209.994
=0.40886121

Metacare Co's gross margin of this year was 0.26955282. Metacare Co's gross margin of last year was 0.40886121. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=39947.536/183984.992
=0.21712388

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=22209.994/121651.386
=0.18257083

Metacare Co's asset turnover of this year was 0.21712388. Metacare Co's asset turnover of last year was 0.18257083. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Metacare Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Metacare Co (XKRX:118000) has a Piotroski F-Score of 4 as of Sep. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Metacare Co and its competitors. This is near median its historical median of 4.00. Over the past decade, Metacare Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Metacare Co ranks #599 out of 985 companies in the Drug Manufacturers industry, placing it in the top 60.8%.
Is Metacare Co's Piotroski F-Score too high?
Metacare Co's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Metacare Co's value of 4 is 20% below this industry median. Based on the distribution chart, Metacare Co ranks #599 out of 985 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Metacare Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Metacare Co's Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Metacare Co ranks #599 out of 985 companies for Piotroski F-Score. This places Metacare Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Metacare Co's value of 4 is 20% below this benchmark. Historically, Metacare Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Metacare Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metacare Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Metacare Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metacare Co's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metacare Co stock overvalued right now?
Based on GuruFocus' analysis, Metacare Co (XKRX:118000) is currently considered Possible Value Trap. The stock's GF Value™ is ₩5,177.27, compared to a current price of ₩1,328.00 — trading 74.3% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Drug Manufacturers industry median of 5.00. Metacare Co's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Metacare Co (XKRX:118000), the current Piotroski F-Score is 4 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metacare Co (XKRX:118000) Overvalued in 2026?

Based on GuruFocus' analysis, Metacare Co stock appears to be undervalued. The current stock price of ₩1,328.00 is trading 74.3% below its estimated GF Value™ of ₩5,177.27. GuruFocus considers Metacare Co to be Possible Value Trap.

Key valuation signals for XKRX:118000:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: ₩5,177.27 vs. price of ₩1,328.00 (74.3% below fair value)
  • GF Score™: 42/100 with 9 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#599 of 985)

No single metric tells the full story. See the XKRX:118000 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Metacare Co Business Description

Address 202, 156, Byeongjeomjungang-ro, Jinan-dong, Dream Buildiing, Gyeonggi-do, Hwaseong-si, KOR
Metacare Co Ltd formerly Smedi Co Ltd has established a hospital in Jeju and exports various types of medical equipments. The company also built its own hospital in China and India and plans to expand its business in Spain and Dubai. The Company and its subsidiaries are divided into pharmaceutical business, medical business, wireless device business, investment and others according to business characteristics by business sector.
42GF Score

Get the complete analysis for XKRX:118000

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩1,328.00
Price
₩5,177.27
GF Value